WASHINGTON--(BUSINESS WIRE)--New research contradicts promises of savings at the pharmacy counter for Medicare beneficiaries from the Inflation Reduction Act’s (IRA) drug pricing provisions. In fact, ...

The cost of buying the opioid antidote naloxone is out of reach for many uninsured Americans, a hurdle that may keep the treatment from saving more people who overdose on opioids, according to a new ...

The Inflation Reduction Act’s limit on Medicare Part D spending leads to significant savings for patients prescribed oral chemotherapy ANN ARBOR, Michigan — As prescription oral chemotherapies have ...

Cancer patients who have health plans with high deductibles may approach treatment differently because of high out-of-pocket costs, a Dec. 22 Jama Network Open study found. The study of nearly 135,000 ...

More than 125,000 Medicare Part D beneficiaries will pay lower out-of-pocket costs for ultra-expensive medications thanks to the $2,000 out-of-pocket cap included in the Inflation Reduction Act (IRA), ...

The No Surprises Act appears to be reducing out-of-pocket costs for consumers, with a new study from Harvard University and Mass General Brigham showing significant decreases in out-of-pocket spending ...

Outpatient radiology services have more work to do with explaining price transparency to patients, a recent University of California Irvine and University of Michigan study found. The study, published ...

Spending on children's behavioral health accounted for 40% of all medical expenditures, according to 2022 data, nearly doubling since 2011, local researchers said. Pediatric behavioral health ...